Immunome (IMNM) Net Income towards Common Stockholders (2019 - 2026)
Immunome posted quarterly Net Income towards Common Stockholders of -$59.3 million for Q1 2026, down 32.92% year-on-year from -$88.5 million in Q1 2025, and up 18.57% on a QoQ basis from -$72.9 million in Q4 2025.
Immunome (IMNM) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$59.3 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 32.92% year-over-year to -$59.3 million; the trailing twelve-month figure through Mar 2026 stood at -$238.8 million (down 9.48% YoY), and the FY2025 full-year result was -$224.1 million, up 26.71% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$59.3 million, up from -$72.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.3 million in Q3 2023 and bottomed at -$132.3 million in Q1 2024.
- The 5-year median for Net Income towards Common Stockholders is -$44.6 million (2025), against an average of -$43.2 million.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders tumbled 2859.05%; it then soared 66.26% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$7.8 million in 2022, then sank by 1089.75% to -$92.6 million in 2023, then rose by 10.43% to -$83.0 million in 2024, then climbed by 12.18% to -$72.9 million in 2025, then grew by 18.57% to -$59.3 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$59.3 million (Q1 2026), -$72.9 million (Q4 2025), and -$60.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immunome | 2.47 Bn | 1.89 Bn | - | -59.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.33 Mn |
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -60.14 Mn |
| Jun 30, 2025 | -46.48 Mn |
| Mar 31, 2025 | -44.64 Mn |
| Dec 31, 2024 | -82.97 Mn |
| Sep 30, 2024 | -50.52 Mn |
| Jun 30, 2024 | -40.01 Mn |
| Mar 31, 2024 | -132.30 Mn |
| Dec 31, 2023 | -92.63 Mn |
| Sep 30, 2023 | -4.35 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -4.47 Mn |
| Dec 31, 2022 | -7.79 Mn |
| Sep 30, 2022 | -9.16 Mn |
| Jun 30, 2022 | -8.93 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Dec 31, 2021 | -7.85 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -5.74 Mn |
| Mar 31, 2021 | -3.90 Mn |
| Dec 31, 2020 | -4.07 Mn |
| Sep 30, 2020 | -2.82 Mn |
| Jun 30, 2020 | -2.72 Mn |
| Mar 31, 2020 | -2.66 Mn |
| Dec 31, 2019 | -2.89 Mn |
| Sep 30, 2019 | -2.72 Mn |